ENTRY       D11768                      Drug
NAME        Pacritinib (USAN/INN);
            Vonjo (TN)
PRODUCT     VONJO (CTI BioPharma Corp.)
FORMULA     C28H32N4O3
EXACT_MASS  472.2474
MOL_WEIGHT  472.5787
CLASS       Antineoplastic
             DG01918  Tyrosine kinase inhibitor
            Anti-inflammatory
             DG01985  Disease modifying anti-rheumatic drug (DMARD)
              DG02020  JAK inhibitor
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
REMARK      ATC code: L01EJ03
            Product: D11768<US>
EFFICACY    Antineoplastic, Tyrosine kinase inhibitor
  DISEASE   Myelofibrosis [DS:H01605]
TARGET      JAK2 [HSA:3717] [KO:K04447]
            FLT3 (CD135) [HSA:2322] [KO:K05092]
  PATHWAY   hsa04151(2322+3717)  PI3K-Akt signaling pathway
            hsa04640(2322)  Hematopoietic cell lineage
            hsa05200(2322+3717)  Pathways in cancer
            hsa05202(2322)  Transcriptional misregulation in cancer
METABOLISM  Enzyme: CYP3A4 [HSA:1576]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01E PROTEIN KINASE INHIBITORS
                L01EJ Janus-associated kinase (JAK) inhibitors
                 L01EJ03 Pacritinib
                  D11768  Pacritinib (USAN/INN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Molecular Target Inhibitors
               Pacritinib
                D11768  Pacritinib (USAN/INN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG01918  Tyrosine kinase inhibitor
               D11768  Pacritinib
             Anti-inflammatory
              DG01985  Disease modifying anti-rheumatic drug (DMARD)
               DG02020  JAK inhibitor
                D11768  Pacritinib
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                D11768  Pacritinib
            Drug classes [BR:br08332]
             Immunological agent
              DG02020  JAK inhibitor
               D11768  Pacritinib
             Antirheumatic agent
              DG01985  Disease modifying anti-rheumatic drug (DMARD)
               D11768  Pacritinib
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Receptor tyrosine kinases (RTK)
               PDGFR family
                FLT3 (CD135)
                 D11768  Pacritinib (USAN/INN) &lt;US&gt;
              Non-receptor tyrosine kinases
               JAK family
                JAK2
                 D11768  Pacritinib (USAN/INN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11768
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11768
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D11768
DBLINKS     CAS: 937272-79-2
            PubChem: 405226634
            PDB-CCD: 6T3
ATOM        35
            1   C8y C    21.4200  -14.0000
            2   N4x N    21.4200  -15.4000
            3   C8y C    22.6100  -16.1000
            4   N5x N    23.8700  -15.4000
            5   C8x C    23.8700  -14.0000
            6   C8x C    22.6100  -13.3000
            7   N2x N    22.6100  -17.5000
            8   C8y C    20.2300  -13.3000
            9   C8x C    20.2300  -11.9000
            10  C8x C    18.9700  -11.2000
            11  C8x C    17.7800  -11.9000
            12  C8y C    17.7800  -13.3000
            13  C8x C    18.9700  -14.0000
            14  C1x C    16.5900  -14.0000
            15  O2x O    15.4000  -13.3000
            16  C1x C    14.2100  -14.0000
            17  C2x C    14.2100  -15.4000
            18  C2x C    15.4000  -16.1000
            19  C1x C    15.4000  -17.5000
            20  O2x O    16.5900  -18.2000
            21  C1x C    17.7800  -17.5000
            22  C8y C    18.9700  -18.2000
            23  C8y C    18.9700  -19.6000
            24  C8x C    20.1600  -20.3000
            25  C8x C    21.4200  -19.6000
            26  C8y C    21.4200  -18.2000
            27  C8x C    20.1600  -17.5000
            28  O2a O    17.7547  -20.2951
            29  C1b C    16.5663  -19.6023
            30  C1b C    15.3699  -20.2865
            31  N1y N    14.1887  -19.5981
            32  C1x C    14.2223  -18.2001
            33  C1x C    12.9055  -17.7373
            34  C1x C    12.0584  -18.8466
            35  C1x C    12.8517  -19.9950
BOND        39
            1     1   2 1
            2     2   3 1
            3     3   4 1
            4     4   5 2
            5     5   6 1
            6     1   6 2
            7     3   7 2
            8     1   8 1
            9     8   9 2
            10    9  10 1
            11   10  11 2
            12   11  12 1
            13   12  13 2
            14    8  13 1
            15   12  14 1
            16   14  15 1
            17   15  16 1
            18   16  17 1
            19   17  18 2
            20   18  19 1
            21   19  20 1
            22   20  21 1
            23   22  23 2
            24   23  24 1
            25   24  25 2
            26   25  26 1
            27   26  27 2
            28   22  27 1
            29   26   7 1
            30   22  21 1
            31   23  28 1
            32   28  29 1
            33   29  30 1
            34   30  31 1
            35   31  32 1
            36   32  33 1
            37   33  34 1
            38   34  35 1
            39   31  35 1
///
